6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine | 79932-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine
• 英文别名: 6,6-Dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine；6,6-dimethyl-5,7-dihydro-4H-1,3-benzothiazol-2-amine
• CAS: 79932-22-2
• 化学式: C₉H₁₄N₂S
• 分子量: 182.29
• InChiKey: XELVDVCUWODGKX-UHFFFAOYSA-N

物化性质

• 沸点：
  312.6±11.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.17h， 生成 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid
  参考文献：
  名称：

  HMOX1 inducers

  摘要：

  本发明涉及结构（I）的化合物作为血红素氧合酶1（HMOX 1）诱导剂。本发明还涉及一种控制哺乳动物体内血红素氧合酶1的活性或数量，或活性和数量的方法。这里提供了变量的定义。

  公开号：

  US10766888B1
• 作为产物：
  描述：

  3,3-二甲基环己酮 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 6.5h， 生成 6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine
  参考文献：
  名称：

  Discovery of Imidazo[2,1-b]thiazole HCV NS4B Inhibitors Exhibiting Synergistic Effect with Other Direct-Acting Antiviral Agents

  摘要：

  The design, synthesis, and SAR studies of novel inhibitors of HCV NS4B based on the imidazo[2,1-b]thiazole scaffold were described. Optimization of potency with respect to genotype 1b resulted in the discovery of two potent leads 26f (EC50 = 16 nM) and 28g (EC50 = 31 nM). The resistance profile studies revealed that 26f and 28g targeted HCV NS4B, more precisely the second amphipathic alpha helix of NS4B (4BAH2). Cross-resistance between our 4BAH2 inhibitors and other direct-acting antiviral agents targeting NS3/4A, NS5A, and NS5B was not observed. For the first time, the synergism of a series of combinations based on 4BAH2 inhibitors was evaluated. The results demonstrated that our 4BAH2 inhibitor 26f was synergistic with NS3/4A inhibitor simeprevir, NS5A inhibitor daclatasvir, and NS5B inhibitor sofosbuvir, and it could also reduce the dose of these drugs at almost all effect levels. Our study suggested that favorable effects could be achieved by combining 4BAH2 inhibitors such as 26f with these approved drugs and that new all-oral antiviral combinations based on 4BAH2 inhibitors were worth developing to supplement or even replace current treatment regimens for curing HCV infection.

  DOI：

  10.1021/jm501934n

文献信息

• [EN] SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS SULFONYLAMINOPYRIDINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016001341A1

  公开（公告）日：2016-01-07

  Provided are sulfonylaminopyridine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

  提供了一种磺酰氨基吡啶化合物，它们是ITK激酶的抑制剂，包含这些化合物的组合物以及治疗由ITK激酶介导的疾病的方法。具体来说，提供了Formula (I)、(II)或(III)的化合物，立体异构体、互变异构体、溶剂合物、前药或其药用可接受的盐，其中n、R1、R2、R3、R6和R7在此处定义，包括含有该化合物和药用可接受的载体、辅料或载体的药物组合物，使用该化合物或组合物进行治疗的方法，例如，用于治疗患有由ITK激酶介导的疾病或病况的患者。
• [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS<br/>[FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES EN TANT QU'INHIBITEURS DE JAK2
  申请人：AJAX THERAPEUTICS INC

  公开号：WO2021226261A1

  公开（公告）日：2021-11-11

  The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

  本公开提供了6-杂芳氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物，用于抑制JAK2。
• [EN] IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS<br/>[FR] DÉRIVÉS IMIDAZO[2,1-B]THIAZOLE ET 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE UTILES EN TANT QU'INHIBITEURS DE S100
  申请人：ACTIVE BIOTECH AB

  公开号：WO2016042172A1

  公开（公告）日：2016-03-24

  A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder,an autoimmunity disorder or a neurodegenerative disorder.

  化合物的化学式（I）或其药用盐。该化合物可用于治疗癌症、炎症性疾病、自身免疫性疾病或神经退行性疾病。
• Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors
  申请人：Active Biotech AB

  公开号：US10385069B2

  公开（公告）日：2019-08-20

  A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder, an autoimmunity disorder or a neurodegenerative disorder.

  式 (I) 的化合物或其药学上可接受的盐。该化合物可用于治疗癌症、炎症性疾病、自身免疫性疾病或神经退行性疾病。
• HMOX1 INDUCERS
  申请人：Mitobridge, Inc.

  公开号：EP3952990A1

  公开（公告）日：2022-02-16